RON confers lapatinib resistance in HER2-positive breast cancer cells

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 43-50

  Wang, Quanren ^a   Quan, Haitian ^a   Zhao, Jie ^a   Xie, Chengying ^a   Wang, Lei ^a   Lou, Liguang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

HER2; HER2 targeted agents; Lapatinib resistance; RON

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORETINIB; LAPATINIB; MGCD 265; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN RON; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CLONE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IC 50; INTRACELLULAR SIGNALING; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN TARGETING;

HER2; HER2-TARGETED AGENTS; LAPATINIB RESISTANCE; RON;

ANILIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITORY CONCENTRATION 50; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIDINES; QUINAZOLINES; QUINOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84883793323     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.022     Document Type: Article

References (36)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Moasser M.M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007, 26:6577-6592.
3. Ryan Q., Ibrahim A., Cohen M.H., Johnson J., Ko C.W., Sridhara R., Justice R., Pazdur R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119.
4. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Cajal S.R.Y., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99:628-638.
5. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., Kay C., Um I.H., Langdon S., Goryanin I., Harrison D.J. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009, 69:6713-6720.
6. Eichhorn P.J.A., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
7. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., Sahin A.A., Esteva F.J., Hortobagyi G.N., Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
8. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde M., Gonzalez-Angulo A.M., Mills G.B., Dave B., Chang J.C., Liebler D.C., Arteaga C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
9. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.M., Gilmer T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009, 69:6871-6878.
10. Wang M.H., Lee W., Luo Y.L., Weis M.T., Yao H.P. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J. Pathol. 2007, 213:402-411.
11. Wang M.H., Wang D., Chen Y.Q. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003, 24:1291-1300.
12. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr. Cancer Drug Targets 2003, 3:31-40.
13. Wagh P.K., Peace B.E., Waltz S.E. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv. Cancer Res. 2008, 100:1-33.
14. O'Toole J.M., Rabenau K.E., Burns K., Lu D., Mangalampalli V., Balderes P., Covino N., Bassi R., Prewett M., Gottfredsen K.J., Thobe M.N., Cheng Y., Li Y.W., Hicklin D.J., Zhu Z.P., Waltz S.E., Hayman M.J., Ludwig D.L., Pereira D.S. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006, 66:9162-9170.
15. Maggiora P., Marchio S., Stella M.C., Giai M., Belfiore A., De Bortoli M., Di Renzo M.F., Costantino A., Sismondi P., Comoglio P.M. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998, 16:2927-2933.
16. Welm A.L., Sneddon J.B., Taylor C., Nuyten D.S.A., van de Vijver M.J., Hasegawa B.H., Bishop J.M. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc. Natl. Acad. Sci. USA 2007, 104:7570-7575.
17. Lu Y., Yao H.P., Wang M.H. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 2007, 257:157-164.
18. Wang L., Xu Y., Fu L., Li Y., Lou L. (5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition. Cancer Lett. 2012, 324:75-82.
19. Zou H.Y., Li Q.H., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., Christensen J.G. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67:4408-4417.
20. Patnaik A., Besterman J., Tolcher A.W., Mehran M., Drouin M., Maroun C., Bonfils C., Beeram M., Martell R., Papadopoulos K. MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience. EJC Suppl. 2010, 8:125-126.
21. Qian F., Engst S., Yamaguchi K., Yu P., Won K.A., Mock L., Lou T., Tan J., Li C., Tam D., Lougheed J., Yakes F.M., Bentzien F., Xu W., Zaks T., Wooster R., Greshock J., Joly A.H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009, 69:8009-8016.
22. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N.X., Li L.T., Xia G., Steensma R., Chopiuk G., Jiang J.Q., Wan Y.Q., Ding P., Liu Y., Sun F.X., Schultz P.G., Gray N.S., Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 2007, 104:270-275.
23. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.Y., Nematalla A., Wang X.Y., Chen H., Sistla A., Luu T.C., Tang F., Wei J., Tang C. Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46:1116-1119.
24. Das J., Chen P., Norris D., Padmanabha R., Lin J., Moquin R.V., Shen Z.Q., Cook L.S., Doweyko A.M., Pitt S., Pang S.H., Shen D.R., Fang Q., de Fex H.F., McIntyre K.W., Shuster D.J., Gillooly K.M., Behnia K., Schieven G.L., Wityak J., Barrish J.C. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006, 49:6819-6832.
25. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
26. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., Hocker M., Treiber D.K., Zarrinkar P.P. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29:1046-1051.
27. Zhang Y., Kaplan-Lefko P.J., Rex K., Yang Y., Moriguchi J., Osgood T., Mattson B., Coxon A., Reese M., Kim T.S., Lin J., Chen A., Burgess T.L., Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 2008, 68:6680-6687.
28. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
29. Chen C.T., Kim H., Liska D., Gao S.Z., Christensen J.G., Weiser M.R. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol. Cancer Ther. 2012, 11:660-669.
30. Shojaei F., Lee J.H., Simmons B.H., Wong A., Esparza C.O., Plumlee P.A., Feng J.L., Stewart A.E., Hu-Lowe D.D., Christensen J.G. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010, 70:10090-10100.
31. Benvenuti S., Lazzari L., Arnesano A., Li Chiavi G., Gentile A., Comoglio P.M. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res. 2011, 71:1945-1955.
32. McClaine R.J., Marshall A.M., Wagh P.K., Waltz S.E. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia 2010, 12:650-658.
33. Fialin C., Larrue C., Vergez F., Sarry J.E., Bertoli S., Mansat-De Mas V., Demur C., Delabesse E., Payrastre B., Manenti S., Roche S., Recher C. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia 2013, 27:325-335.
34. Zhou Y.Q., He C., Chen Y.Q., Wang D., Wang M.H. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003, 22:186-197.
35. Angeloni D., Danilkovitch-Miagkova A., Ivanova T., Braga E., Zabarovsky E., Lerman M.I. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 2007, 26:4499-4512.
36. Bardella C., Costa B., Maggiora P., Patane S., Olivero M., Ranzani G.N., De Bortoli M., Comoglio P.M., Di Renzo M.F. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 2004, 64:5154-5161.